MERTK and non-small cell lung carcinoma: We have previously demonstrated that the combination of an anti-MerTK (αMerTK) antibody, αPD1, and radiotherapy increased the activated CD8+ and NK cell populations within the abscopal TME, leading to delayed abscopal tumor growth, improved survival rates, and reduced numbers of lung metastases in a murine metastatic adenocarcinoma NSCLC model [4].